Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis). @RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW

#EULAR2022 Ultrasound may be used to evaluate patients with RA (POS1393) and SSc (POS1394) 👁️Look for B-lines and pleural irregularity Will require training of MSKUS rheumatologists, but another potential application of US in clinical practice @RheumNow @MymaAlbaydaMD @USSONAR_Rh https://t.co/qtnBviKA3w

#POS0713 #EULAR2022 Exploratory analyses from Phase 2 RCT showed numerically more patients treated with BIIB059, a BDCA2 inhibitor achieved a clear (CLASI of 0-1) and almost clear cutaneous #lupus (CLASI 0-3). Looking forward to Phase 3 results in the next few years @RheumNow https://t.co/dDbwYCx7zT

RheumNow’s expanded coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its faculty.

Watch: EULAR 2022 - Day 1 Faculty Recap Pane Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more. https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa

• https://bit.ly/3GF2mOG

No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest. @RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8

“Post-exertional fatigue is real (in #LongCovid), not their fault. Validate their symptoms. Pain is secondary.”- Dr. @LCalabreseDO #EULAR2022 @rheumnow https://t.co/hDvxJfb14f

#POS0721 #EULAR2022 Are Aspirin + LMWH enough to prevent Adverse Pregnancy Outcomes (preterm, pregnancy loss, eclampsia) in High Risk Triple Antiphospholipid abs+ve + Low C3/C4? An Italian study of 128 patients said NO. Add Hydroxychloroquine @RheumNow https://t.co/927sZoHZEj

JAKi for nonradiographic axSpA One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. And the question of the utility of JAK inhibitors for the treatment of axSpA has been on the rise. https://t.co/xq8ICyKKv0 https://t.co/o2iUgyU60A

• https://bit.ly/3PZZccS

Germano et al. Temporal artery abnormality on clinical exam predicts biopsy + . Arterial thickening and reduced pulse strongest predictors @RheumNow #EULAR2022 POS0820 https://t.co/Rs36ALSoJb

Merola et al. Risankizumab on MDA and DAPSA in KEEPsAKE 1 and 2. Week 24 MDA 25.0/25.6% vs 10.2/11.4%. DAPSA LDA+REM 41.2/36.8% week 24, 59.2/44.6% week 52 @RheumNow #EULAR2022 POS1029 https://t.co/Uz7kA76pMH

About 50% w/ #LongCOVID has persistent Sx's at 6 mos (fatigue, muscle weakness, insomnia, anxiety, depression, dyspnea). Risks: female, obesity &prior mechan ventilation. Interestingly, the pts have inc CRP levels. DLCO is low. – Prof R Mostard #EULAR2022 @rheumnow https://t.co/8jCEObjf5I

Risk factors associated with non-remission/LDA in PsA pts: Baseline TJC>3, SJC>5 CRP>10 HAQ>0.5 enthesitis/dactylitis BMI>30 sDMARD use @RheumNow #EULAR2022 ABST#POS0080